With FDA nod, Bayer's Lynkuet enters US market for nonhormonal menopause symptom meds

Bayer has received FDA approval for Lynkuet (elinzanetant), a dual neurokinin (NK1 and NK3) targeted therapy for moderate to severe menopausal vasomotor symptoms, including hot flashes and night sweats. This approval expands the limited non-hormonal treatment options and positions Lynkuet for a U.S. launch next month, competing with Astellas' Veozah, which targets only NK3 and carries a black box warning for liver damage, potentially offering Lynkuet a competitive advantage. With a global market of 1.2 billion menopausal women projected by 2030, Bayer anticipates peak annual sales of €1 billion ($1.16 billion) for Lynkuet, contrasting with Veozah's recent underperformance against sales targets.

Analysis

Bayer has secured FDA approval for Lynkuet (elinzanetant), a dual neurokinin (NK1 and NK3) targeted therapy for moderate to severe menopausal vasomotor symptoms, including hot flashes and night sweats. This approval follows earlier clearances in the U.K., Australia, Canada, and Switzerland, addressing a substantial unmet medical need given that up to 80% of women experience hot flashes, with over one-third reporting severe symptoms. The global population of menopausal women is projected to reach 1.2 billion by 2030, presenting a significant market opportunity for this new treatment.

Lynkuet enters a competitive landscape, directly challenging Astellas' Veozah, which targets only NK3 receptors and carries a black box warning for potential liver damage. Bayer's drug, lacking this specific warning, may gain a significant safety perception advantage in the market. Clinical trials demonstrated strong efficacy, with over 80% of patients achieving at least a 50% reduction in vasomotor symptom frequency by Week 26, alongside improvements in sleep and quality of life.

Bayer anticipates peak annual sales for Lynkuet to reach €1 billion ($1.16 billion), a projection that contrasts sharply with Veozah's recent underperformance against its sales targets, having achieved 33.8 billion JPY ($221.25 million) in FY2024. While Lynkuet's safety profile appears favorable compared to Veozah, potential side effects such as "daytime impairment" and increased liver blood test values warrant careful monitoring post-launch.

Key Decisions for Investors

• Investors should closely monitor Lynkuet's initial U.S. launch performance and market penetration against Bayer's €1 billion peak sales projection, especially in light of competitor Veozah's underperformance.
• Assess the impact of Lynkuet's perceived safety advantage, specifically the absence of a black box warning, on its market share capture relative to Astellas' Veozah and other non-hormonal treatment options.
• Track any post-market surveillance data or further regulatory actions concerning Lynkuet's reported side effects, particularly liver-related concerns, as these could influence long-term market acceptance and sales trajectory.